# Mirtazapine

## Apa-Mirtazapine O.D.T. 30mg

| TAH Drug Code      | [OMIRT3](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMIRT3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Major depressive disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Adults: Initial dose is 15 or 30 mg/day (higher dose at night). Effective dose typically ranges from 15-45 mg. Treatment should continue for 4-6 months until symptoms fully resolve， then gradually taper off. Symptoms usually improve within 2-4 weeks; if not， increase to maximum dose. If no improvement after an additional 2-4 weeks， discontinue treatment.                                                                                                                                                                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Contraindications  | Hypersensitivity to mirtazapine or any component of the formulation. Use of monoamine oxidase inhibitors (MAOIs)， including IV methylene blue (concurrently or within 14 days of stopping an MAOI).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Common: Constipation (13%)， Xerostomia (25%)， Asthenia (8%)， Dizziness (7%)， Disturbance in thinking (3%). Serious: Prolonged QT interval， Torsades de pointes， Ventricular tachycardia， Hyponatremia (<0.1%)， Serum cholesterol above reference range (15%)， Serum triglycerides above reference range (6%)， Weight gain (12%)， Increased appetite (17%)， Agranulocytosis (0.1%)， Neutropenia， ALT/SGPT level raised (Up to 2%)， Aspartate aminotransferase serum level above reference range (<1%)， Cirrhosis of liver (<0.1%)， Liver function tests outside reference range (0.1-1%)， Seizure， Somnolence (54%)， Angle-closure glaucoma (0.1-1%)， Mania (0.2%)， Suicidal thoughts， Suicide， Serotonin syndrome (<0.1%) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/mirtazapine-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

